ࡱ> n>I"0ūyDSPNG  IHDRqzsRGB pHYs+HIDATx^yս63,G hX "lA @ ˃zeѫ e"ȾE AUva؞oUZS]?]}9:ӿ>N|  @ 82@@ Si #@LuǑ\@ @pG#  @L  1GrA@J@@b; 16 ;Tw@b*m@w8  T Sq$@@ H. Si #@LuǑ\@ @pG#  @L  1GrA@J@@b; 16 ;Tw@b*m@w ]|ٝ-K?~vuVjʋ ?uOqf< \0 BS ~}+4 ,pnR~{ o?5* @ȗ15_\$F@ 1Ɓ ;Tw@b*m@w8  T Sq$@@ H. Si #@LuǑ\@ @pG1ɓW]uUBUwm۶-o^o݁!@)z…=z:t(\=ڰa%K[-ZZO# c ֭;o޼?~|NNNv-zZ Y  O>܌[˗ּy+W]At M4YjUTI}HU򖔯&DtpLrz55dL-]'.^X;+.VXvvv~}3y iӦl.aÆ >ލXK:ꞎ1 ?T^U(|Mb=r-i@pW cιCW͛7o:u5"7@$wLmܸ*aF]!Bo5kA@]\4pʕ+k·2er_P|kDn 8HʘjULԮ]f-a͚5e˖uRs  @T]ps)^TҌ3- ."7@ $AL ĉI, G )c P4@ &ᢰ > P4@ &ᢰ > P4@ &ᢰ > P4@ &ᢰ > P4@ z~6mtRw@-@Li999 $ZXjU*U<Y#IhxF1OG $15eG1OG $15eG1OG $15eG1OG $15eG1OG $15Gwޅٳ'%c  Sݳ$'@ z{Nz9 {{HL-#158EL-#158EL-#158EL-#158EL-#1է|uQ,@PT MߴiSb!S ԯ_I&IQT  `0cƌUVX@ 15# L̉T D Fs@ S9 @hhB| 3b3'R! MM@p&@LuD*@ S 9 ΜjӦM 3Eȷ15d܀OmPZ@@6G@T6^zd @ cݻ۶m["oi߾ކ›oydz1}t5  iL=zhÆ ,Yr&oYhje՟۰aI={ʄPS@4iLU\i׮ݱE/68X>|ezkV  gիW bȐ!aÆʕ+t<5hޢzܝ)Bɓ~Z-]ԋSmss׮]~iN˗}Xh'N\xpG .+V,;;ꄫƇGhzҥQF~+ܹs#|m\={@MaU޽{O6mԩxFFZTR^\~)++ٳW_}u]ٻLrss8˗/ݎk>|X O>뮻SܤʙF-OcԎPB Wi߾};w^v;ToB Z/[,=&<ՙĐ1l&V_衇|[< @rT 䪓5n߾{-ʊ+[N WSBŐ@J-1la yw3(7U9lң6n_~#G=# 8Eü5]U-Ν[ (jƍ޺FiСz[~}'5<ۊ;I4fWc ;;E }:' >F^z(7Tټy֩S'˚5kƺFISvƍ~S[N'r "G1t@uL悗f͚Z~kXd+W]+4hpmu%c iL8pB-S|5.߿Wbz!"yQJNJ5. @J 4^]۵k̼Es>hlٲ@ |*bΤΞ=LCO[0j  @j v/n4WŰYݮ{em~rٳnЍ}]A˶ 1 8ק՞8q齱  pA$ H )c9sVC@WTC~ؐi|%Ba@M @ ̡"  HdLOg͚ռy{@0߿_3%J93f#4^ݨy  ob&mԨΥ) Μ9Żf@ xSǎs%&6mJR7@ Gtnj?&?c*^-okOoVTӤI=aݫ>7x 8*>㙙*_|a.GҩS2nIAI :]')S^TXѾ&;;{ȑ>7x 8*jm۶ݱcСCo&Seˮ[k׮ŋW/Yfk׮.VrR\  [cꬋ~GZtӧ?oi( *Ο?… * @Hjb8 u릳פn"@W1U?w&KҵW#rov*䢧 2A(1* Gvڴizmwed PbΝ;-AVJ@ m?p͚5ڵk8:{lJ:_tٲeG}˖-zZKT ,駟J[lYWHD]@B !dɒ=z0Tw}oߞPB"KØ)Λ7OTVBi @N~?P)-t.@ xS>Bi~@Z۹ LJsʹI&QWZ5 @9еf4Ѡa&:969)S}`A|.@LrR#jjmiӦϝI  @LM*TЊd @c^]!A@ \gϞiQ̨֬:EHIbjJP)@ xSϟ8/)@Hvbj.]pnݺ͙3쭄#8*jߺ]U3vԉH@ < 5[ Gp"UL}jժUH{!knnR@ xS_M6>}zѢEGرs-]μ" U~I 4\Ҟ~$GI/.{G+cc֭暘7gC@o0_7x115_z1$615n99q+;B (ǘ~Y;wO-{6ϟ?uVMggr)#u4˗/_pO L6MySutHEL՝˗/߰a͛.]2efɓ'45Kɓ'5sdrmk6G8W&p\,0#?p͚5j׮ݳ>;{l{@ӧϲeˎ9)L G^[@MI.*8*jw˖-/^EW^ ,駟J[l@x xSu]4=z0ToߞPc̾@#aL-^ByJm%爲@D xS5J;tɹD] Obfux≘+{mۖ[ېY!C\wuiw9"D[o]cl;zhÆ ,Yr&oz]tUVG'N7NǶSB@ ^TuU,MCƏy tZҢzY'MvOS5.I+VİG6A@^T'cJxyu5eذaz0K֨&MT^hXk>& PޫuYgUY5rϺ~zm[^=SnM5S@me5jdXKhY4bseǞcs@^=FNG:?j_Y+pIfKff'|rwh&5φ[Vֿy  I2'MD4 t&iL7aL۷1ct7xCkY=t w{e`Sm&jz.ͨQ}џgh׮]R4j癫;VbN0g1.vۀ3Hdr[npbSș8ܣ֟i? { q(Øy輒,tU.V H+LvRú$%i 7͞Jk׮0׮sRkS]n:sJUgI3Z $ӏ,m=GúWW*Emi\2IҦM4W_}UZ؞P_]gϞo]Oе:e4?s+)T<=A'/K] ]VJ3 HJM/W\QjUob Svm}.+{t38puY-gկ_?y+uOu#9rڴiitש[ b(˩S/tmѢOuT4GA19J7Z}+sPzI6Tz{)oٷo_Ȕ0{tU]߂&gurO-OojԨw^+utmVlYJ+TwLԏ>AQ @?5* @~W0hDN0i|_'GfPFtQ҉UEƍ׺Z9 ^OZgt4P #2GRI T 5Bpɯĉ -@Hck; 'O" @R9s΄*V x$1# E@ ^TE?)f $=T RE@'^p<5*Tx4 kT(@ \ܟ-#SD@ i> kT(@ \ܟ-#SD@ i> k5kV] ! 8c 7(QhѢW-_|.]V\g@\*~xʌ˦+f )[5knrY[ ΝiӦp۸znE@ MooySo^vsΙ8!ܑ#G׿{RsD֨1:5q毿lٲ15r ~}+Q @T~utΜ9eʔT'58j?.\0iVVVq}8%P9 $VZ;v :n2T[n]׮]/٬YkZ+!̙T͛N:X;ͧܢ&@0T5o|:]{i=o?4YsAӈ#tU*q *jW4<ޘʕ+kk|Xj}oDS:j-S"l >^ԷzKc=\"֢9֬YI0 @ >^T WVJ*iXh]7xnlM5ݱ *lҔl,b'Np=s2D@ 6bԩS^s:ȪbM3j*V x$՜Ԛ!j2`˜Q @@|0  n^#E@J@@bn;U!@*ULMh9   &]"1Ǐ]=_OpӃQ}৑2BHoc/|ٳ3gI?7o@0>S R ɴtR׌Hzty 8R@} /Wϙ1;@R@j=<UCzd뷿yT@be ߺu…waa`@R@ziswdR-RH R@W15##O> ikK.@@ ͚53:]ty5UΚ5:ڢEp  xSopsrrzQxqqU=pICq@Hbj˖-ˮ]*e 8R@}ן| ӧO  T=;vm3F}F}ݸq5ojhR @t('g ~}+է Moo^Sϟ…' )#ULՕJ֭'Ls" ڥn9sfN4A@t0Z|thI@ԪU+`F1@@ 5OfӦMIѢEGرcɒ%{Wg^SZ @\پ}\y&͛>G $^Vf{MVL!% j7dO5j7ܫWcǎ_" \ۘ;STΝ;뎚ի?;wʧj>} V׬Y3++]vg>uꔥPlٲ#GL<ٷ: @^T=pf˖-/^ET ,駟J…*sR" @*w}Ro W1U>S͛7샺7##C/6mׯ> @܏wV(^xAx MyXzرc֭۰ao6Quf x!rL]f0op׮]d˗/J @B܌vjӦѣGDVsݶmĤA@n|PҪxuC-xwJpl#J b'|]k e˚W]uUnݴRY6nܸb '%  >p-Θ1êj_zp5Gwu}CcQ<@"S׭[g'>x`+z!@R@gZm۶LӺuk+IG k1ҥKfx,E1it@p-5F ip  SVji.^8Vc%9  k1N:ǘ1c"ӼV;# T{ji~V@Tp? +~/\IBO,J}DPsjyKMa<Lwu9i@p]Z 6\df.Բh" ~ڹw}4ϟP]v:uj  Ә:~v[Bo2F}ѳB7(ȑ#c`@ (ӘzjUlȐ!aÆʕ+jNӎ;TRpX`߾}Das@b(t6zQ4S댬I'e#zu֭U֦M7pwnxmݼ?'R &U7j}O={n=hѢzkV[4ONA4~9ɨ:$@@O КI]pOU͛7WٳoSw•SXHs? hBiVVVȃ!_ݟ4oT@ ֫WO&޼y'gYiV80|ӧ{aD 8iLmܸJ?b]tI[PÇiF`@%Ә) +W9ʔ)}5烞oӿdtuߪ^ <ج>J(EH[TKiuofޢ9tWLٲeӌ3Qq@ 4RJ F… 55eiUtmp7eʃ 'Nh.bbA@?IS5sɓHI@@R9sTZ 2J  `@ H. Si #@LuǑ\@ @pG#  @L  1GrA@J@@b; 16 ;Tw@b*m@w8  T Sq$@@ H. Si #@LuǑ\@ @pG#  @L  1GrA@J@@b; 16 ;Tw@b*m@w8  T Sq$@@ H. Si #@LuǑ\@ @pG#  @L  1GrA@J@@b; 16 ;Tw@b*m@w8  T Sq$@@ H. Si #@LuǑ\@ @pG#  ߘ{mۖ[ڷo!di@iL=zhÆ ,Yr&oYhjed^#? iL?~|NNNv-zZp&H# իWC ) 6LoW\ 0Y ._C'N\xpG .+V,;;FN}vnnɴ-y >>EBI3Z$Ԍ}BVsssUwӦM@ԨM S-NjԘ9١CN<):կ% UaLT?c|M=M4+++ڑ+WJ%"@>S6l`jyfSN@&sAJ@biLmܸ4b][f͚au@>FIF{"o۶lٲW_m,”ݯp%SR"i+Suڵkv횙h·5k֘j_&KF@@)~jd]hzHO-"i%ȇjĉ$@#k"iJɓ'  s̩Z*@_ $eL A@Si  #@LuǑ\@ @pG#  @L  1GrA@J@@וk54ؕ@ JpG`ּx:xFN9#-yLO>xM?YvFI}se*-$q냒??M1)QUʤX\{玛JnW53;=jnS+ nڴ隯$={nUV5i$MjySNիWJj9>ӤsTƓ$q޽ͣ8חqgw )+@LMCK@,@L38CHYbjZ* gbj @ SSR1@8 S @RV!YW\(#"wS.\s 3p>״)wݩPڵ󟻓W"ĿẒs SSR+@ So@RSǕZ!_ZPݻwm۶DҾ}{-h)ɓ'*=q^֬Ys=ddd~45jdp8#Feo>]gJ󖓛+%-G'cYȑ#WlVƜajlx{4kFX]H"ߒSL8jpx Nh׮?駟?>''GXޢz47ްaCݺu͛PFu>}8qB/F-#G/8 .,^ L8K,رcM>}ѢE5^ ݻw0DIQjѬY39?L 톉*kZ[oOJ #;;[$Ltϝ;gKW^yeŊYCߦ~ М jSr[LX`uR5 b*VXZ cǎ4d:u$jrv*UjCPGMIcq|>{)\E[2m?aÆn~]0h АDcN:u%pƬYfϞݣG]ioH[B̙3XrwmZQBp}ʼnV5zp,N=>:?HÏ=:J-GhH|ҤIj6:C)>S k9.aVfE]6~f`X L/_^2sK+i4K23.VMȜ3)$~.V4gդؼy֩S@XnڴUVdẆ:tСt7&(̜9S&:l4D8[-Gݮ4\Bp`79ܥn.6c J#xmڴ9z/8l08`o~%ʧe˖ N/pʔ)Kæ+.VY+Wx :t]$oV*?VrEDlݺՌYNرo-G-dɒS\={$p/MAc8 kќ;w,h}@LUʺ0 8زexӨg NJˑƍMђSE@ΧH. Si #@LuǑ\@ @pG#  @L  1GrA@J@@b; 16 ;Tw@b*m ~eΜ95kVpѶ>iӦ-!r˗w}zdVVV%j֬6ddy๗_~uȐgJ:wo_t)?CO,Ufq7{Ŋ7ky W>R!(# #<P}'s֮]ۤIS]R9ݤI ԩ"TyqKN;nG?k}vm?cH =eHOE|wooP-3nE4mɤ]@6Q_ڵko޼9 q{r:GߏW[r-|M@={|7VÕ6>]G8NzW_}=͆ ڶm{X:&YGOUcM|MCTڶmӧ"up@M vʡ|/^߾(\^PU={ĉ:۷I@&GrnnnPFBzVsKkiyy5… _}iR}SVV:%sN/:J`O>_ZsiSN͜9Ӵ|ٳ =nRFԭ*  #7{{Λ<*ALzȞ8ǎ{5k]X1mѢŘ1cԫŤ~p=ʔ) СCVLR͛7M6?χ~̙2,Yk׮]ŋ):KשSW_}|:Y%Kʕ333%Ku]#G:oU_WFRR?Ȫ !:wR)"JԺ8HH퐇)xwjJ#ey*SرHG(`]'W с6pe/'QEa)/`6mF/Vwi/}/_>dX/&LQTb|ݻ[n@X P8u.Z,X@,!!Q>}Bn5p{.܌V$昚ꥃ8?g6رcUqM7KG܇ ><()[$w;CΥ(iRu_ oȡB$X}|pGmB#@ȇ\_8FG'|2.40r^bj #O?+>7A kz(21 ٜ4ݩ;BЭ/qpȲeL}//ROZ!JsK Jn8T]7xCxt+\?SOV η?蠟bׯon8r䈮rV*7f PӍ7jEthZIv"!Ml#BՊVw~Ϟ=;`sOg(D׆$N15ikד~k1kԙեIJ#H;AYw*έbz!&).Z[)[)XC+9/.BpYg@CV9:Z?!"zUyD.:2XIZFP&dDZ ٲTOy_ӵ$fMVi> BR소|*SuAz֎j_䩽ԣJpK̭cl9,{tQUȘhѢV$dy8)*g/kSxvbjj_MdME㊊pz}iH'Xh.@0 ?$)SrtNCd~ph\\΀5hR"!+CWQ:iL4lb_O6[b"&?n0MbVZwZ!G}Л): b$7q4[ 5}A:; έ:x-"iW*E@#_1^{nmķ7VE8 tnuF\ ؇õp >>$9P)QLWʕ+U'gM y>k};S~gSS VT]T<~ tf77u@MAB0:f5r"!CSifE~l^ǔ>HJSSV0Ҁ5ɠbMvVOGaNК%&wdF* WTElx"^:jb(}$b[ GjF׸}>|xSѣ6+++)A(' 'N(][m۶m'Mkfjz)Ux ]+TRZZZnn.\XEkR7=1z˅&;@x(1/u莰%MT5DLMII)(( J;L08#ow^g J@ i'''4>̜8jj;Q @X15qQ=?c.jrnK@B x+Ɜ8CؠlذAZ,A@ފ;v٘1c)IChEotRvGr@@1ULǥ￿qf͚1n@.0YUV?Ԣ1V\YN;  SխT=?SJs8W_}孷:s8 @"15%##NbA@ rpڴiC$g@$`f͚q@'bjD@#@LL@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  @L@@1Վ#  `'^z#G\f  xVNLݴi۴iӤIx`ٲe S;vҥKzpBRq@O ؉ׯ;vlV={L>O>իW馛׿5һᆱ'Po|$F@ ^TPM5L"ɓ?#Z=c/4@ ؉G5{8z4N!4H֓(/!1 @ ؉Nzuxs> Zw,## 1/)i@H HС S+jL!/)@#15jNQ@+@LIn S,Kux#$DT@WTWL$B@ hLs&lqI @ ؉#!` TLPqCdZ{QҫW/ 833u&Vf͚G@Hڷodɒ#ŋ6)S~k׮5ɴ2p@mLCK@, 1Uq1;;gϞN-Z`O+8Y]F@( 1u>|xSѣ6++OުO5lM: 7$YFǯm۶(lRwPv-ƍ;~fr5l/MǎU1c檷VK.~Oז\}d7@@veAE;vrzzMԩ@ĺ:uT]ۗz'vm uVFfQS|@ u?UϤ7oSO-AyM@]7xCZIJJϟ6 Hvjh8]R=|p}i/" vj * Ħ>JY7Tpڴi1^H  ,h֬Y*ʏ vb5\sM7e3Q<@ ؉:g3n^ͳ+, xJNL5c/ST@vbjZZ~ӟj&Jq75 @ ؉7$h PA@0vbWXR  xVNL(S_aZSq@Sۈ! F~L57i@H$1hV+jժ)))^/r"Q@"SoFMSuȑ 5b5J2B1'G&a~_֨Q 饗N:Z@HLի}ݼzӦMCǏ%B@:i$ ChOZ(5Y  {cܹsUMSHMMM5U޺uFׄc! `A~LTg}zN5j4{lW_Y(5Y  {cc}ӝ;w%''%B@z\ꑴ~'.[Lm۶JM Ğz]ws̩]cǴK]tټyu5( "S >x` & @bO~LU333ϟ߻wﴴ45RTrW'@@#]wu .-,,<|;ӯ_?;E&@bR R15&+K@@bjFFl?S&|/ʕ+WDЃ@(@Dbj=,۶m6l).q7n4݆Y@ 1U.Y$h5O?eaӐ@XSgΜJ0 ''ǩ6˚5k@ڵD%\| @9؏[lQ=MV^=B 4x\ͧ~겖/21@(w1bœy~uۻw~M禚5k@@ھ}{o߾+W4}.]ڳgOl2lnf#aS@S }G:t^= YTun:m7^xvyoq| @L؏/I4hPzWZuժUꠤqas  SU)S,ZȌ[Rjժu}޼yG@#kT3ޯ.Z r:uHСCקU_,^Xo/꫟x≝;w۴_F_nj"ĦZzMtٲe~dW6)R#7eggk,6T+VST]R`OUTyl( @| ؏eW  Tufff^{ZҥK ezk!.jqZ%Ç'u(- @l TPsn*W.E! G l& +O(BZfB3GͤVZz?ڵk?]v6jj &#ow^gkEn q!P4c^a1U[gϞXz=t ~].QhlVdjޛ ~a!vo9?dSÞQ$@Pb-KPJ5'_uU 4d5R]T:qDK;ww뷗223'V@ >\UTU_TT k~tV}ܵ SKt8H$˘jq5k/K0ӉK/U3rm۶UEjvajo&n˂ @"Nԟvi;6mڮ'DX=t|dC,9tQnjNIV !ѵ}РA?1=Cz'Yˈ@>J&Mo닫ۜNg뉗@z-Ea-ZNYPN:'+y*Z+s]UyNԏ>Pg~߂xYܮΝ;Wj[lݺnЊ G"UHE:\TEZ|GIZMպU擄5&O@NU]Zzu֧ # kG] PN-5_D@ک.𾩆.[P ;@ dQ$g{W]bU%mw|+|}/~QR\bxw-gL$|I۱%%1 gTQj5({jj"Z~gׯH8iX" @Dbjru-\PY_~kG_4 [4ͺ̝r9Q) @XH԰;k V-9S SÎ&{s4l}4Q9Vx6  };1zu. պ5۲eKIn}wd @b1jX>}lܸtfA@ .Ts,à 67o_j\O\e„ ťQ&#͊ DMNL-ѣmk|3y^o&]U8ԧaafŊfT}KYV<́ D_~L}WU^4*nka+FϡtRjC=᪕ӧ́ D_~LՌ4Fj_j ={dŊ;tTzd QS^qԤB{n֫WOi47[oi ȑ# @\o]5ٵk_ydplڢfK׮]`ĉM4ѺZ;wu'xB/p9  `?wٳgЪג> [aÆUVmԨQJ裏G@@/`?ZK/zվHݻwW#=]㦆ꎤV۴iĚ-uzG躱2Q`v i@@F223''J @ ͘:tGl#N #9u@/`'yMÎlUL2E3ML@bDNL^/{[4iT&! b1C=TC鉚>[[ lؓ! ];1wSw%JEl߾}Ĉ馶K,# ag!SmɧQFƍ۽{1)i{G @(@bz)֟z)/Xk[nEW}4.(# TTwS3H^Z)k ХK;,Q&$F@ :cIt3h}ݧ~Mž;ʹ+7|NUKƍ?肰H @ԙ3g q*>G[iE34mtرf}-j.Zo}ԩ.>G@M1ZRRR|+ߪV-a'k39(F2dSqalrg @ ؄X~{լmnh7o>yl]+.A@ۋUs\tU uҥf-[E-[<իW ĈG}ԡC d$֭ۺu͜#:@cj~ Mq Qן SU2M)n{lzT]4'&$6mr &Jk…z~nS@, D*vG/I @"S_~.^hr@@ T]U_7qJWF%#: .)_A"Tn1իWG(E@,c5kT Hh%\ӺaV-k}3Eyء w@(j /4hРDzgׯ+f&@bM~L5S׬YUՄ3!UJMPC%%= @tTx;5\P n|s)E|@H ؏]vwyyЀﳪ:_A@\TMj*uPD4jqv5rYό s,ZꩧD7, Ġj=z@7ovr۶m۰aôJd uX&MAjr d @Ts743gT8o>p@5  kcjkeegfի䦧]_|EMr駟} u;1+,?W۽{iB d @Բ73R_rgr.]Zoٲݑ Vb12Du裏:t蠋zGtmݺu~]wY9  `WNL;x~ MzjA% 7@؉Vɔ)S-ZԻwﴴJ*UV{c_d `K Fc׫W/MoH?V@SJׯ4@ hLU .28++Rj b1>}lܸرc+L DH c m}MA5¾fѢ{zlݵjR#8Bd 5X˗/aXbEV уlmѢEvvx߯"4SŋVCNzo 9HYf򗿬QFJJJ饗N:e5L &j%j9she[ 0E+zQSuY! F "1U^5e+((P96m4tPmw?F8JNL矯נTӴ>|ѣGmVVVP$|7l i@p)PAU]&uLM]p4~xEY5jhΝR;묳>r'xBo rPUf}%H/BK# ϟ?_T3Ṗtٵ׾9vu.H HE3F۩s^NU8[n5#6k2uUi&NؤI+RvYTU/486]c6-&gU&ߏy_>x(lI eTuU/!իi.>J`+Bq6mN-[֥K0p@%Q^6:jn:f}Y?N:ӯjڳgOq·fˏH;Y;xWک<.纜TaOTaU8{ .@s=WݔPM(UD;orrr{9T3YNE&jWQ{V$QWHuPmۺ)e]E`ju_jʚ_7ٮ]|anþ9%L#QusDH V~L5*zծ]KRSoX LHбcG}k̘1ꔤZ[ƥȖ  ^ "1vY=gc7n1j֬ӛ~w;-Q֩:zg$ @ ؏TZ3UTrv|%}UҬZiEh.N2@J!`o) ?ꗡ*>|e:+#3s⨩}J_D_rQO ##eߨ2#xY_] k7 n?3%{g|^+]IꫯdF#N6"= %S/{[~sWܲ< 5kV"# PR1Uc5rh $/xgkK.[yµG@c۷o1bf1#.Wu_ryµ|@1U9nܸݻwA.s= ]1awD@, D$iz +Թ nJ_'\4 X`LU'W_}Uk@qY뮻n…kPORV`.3$ HLF+7|c1؁tA8l}ԧI(Y&lJ  ;cڗM6;v]L=N]hѷ~/PaXj~a$ S~m͓WVMCk:Lr9ӕRLO2@bA~LU7o>y짟~ZД3glذcLZLH @T=e˖xwdժ[nnn:lIXKr#1 S7:Eg/ ĔZre3bS@l ؉Jc'B.vwGn XŘjbd @TӲ@bJNL*Q@E~L[%Jطo_zaf QS+trrW^Z @/`-jZ7̱cTgid&d DAZL}gׯ۷ ģ g^xUT5ӦMG&ʌ @Xk1U{kDMjjlм⚠s [&  6cﳪ"Ǐ_~n#eF@ ].\.7))e˖J2@xSW\٧O7, xD~L0aBqvyfRM@ ؏˗/+ZjQWRE׈/ G|9TS.] /pΜ9Z>}Gd& T#Xb:81U+^iz  wzOOvQ+o|iFMs"^Sv*ĉ'6iDEEE;wփ4O<_|^# S VZQFIGs|G<"K5@&`?;Ҳeڴi#J͖:{ .@s=WݔnS_@؏˜HpӦM_#T@t ؉~CNHt@RNLMH* @%"1  ؉fT G@SJ! P"15l ċ/5  $7@ ؏ VZոq-[y#$ȕ|W̘1cݺu&=\| lΝGTe?>\d*uAs*w_ⷳKTK{,uVnv%*U$vSxK3 #%bT0)PMII~ithq/_gedfN5<*v}T(kذ+kY#-I|rXj kW??9t5˟w].[8ܺ"tY¿ئu5Ue(Qub:!+U2fPX+CьyCw-Ubjnnn͚55AMUDhj4M>>iӦk6omv!SO?])] U^d_}Vnv)5kf o߾۷-R$pSxK9!4s-Nb$S+C͜9355U7\cDe ++vJ*]UOK+ڶ=+(*{Uzu SRNV8x4i_O*Te%+*s9t"d6̢O:tbÆI&+7iAAOݑW~<99JWnoa7œ^{c&%1˫S;Vܑر|wljwDVLzռNwϛ4z5׷h\KأN< q.=eZ7S5jPn**TM.1R'dQn1uѢEz*G횘Z:xSx)3Dh joV̙5}!įt<}mOR@c* xS "1uʔ)w^q{Z#$/{[n 7Y  ?t ؏[lQNx4  $jB=zYڢzQԢ'v6W\٭[7QZn=wܨ!$ڧɁMk5j۷odɒ#ŋ6`՝:uZthk_7VNv cȑ#5x7޸l2E;4ٳSVV>nܸ;CӸjeJ0v $z9tyƍ]t,4o˕kZtYoiZZɓ5HŊ^ v"' \^fm۶f-[ԫ.CMgM9koA_uMUQ \)v _O=쳋dh"1 :ojk.gNڵkj[ou .,߾&53Ki] 0K(!Ycۏf^?Ow_Ժ&''PzW~7 {0/MXN@LG˘j駟wZ@l^ sy4O݃BW\:`75 G] $j&4NsuÆ z^}999=جYR@SGѬY3=A,Mǎ:fuA:xVV۽{w=KӦo0  tݭTKQ=,߸qcPfM=-*wm--V@Un TvjGԸ;C(0+`?ۭ_ZuՃ.z~ThŢ Sw53֭[7qD  )j:uaϟT @T ë6m:  ) ^ :pB:R)@T=;ڨ5/1+l3],͜#f+B@r`e}v[k2k֬j{>},XP.U-Ncԙ6_qEE)UiJzu֓RTTJԔܤK[MK~cvfKu_!ep9ZVǎKII ,z~~Q5ke[1uUƯ.NKKKӧf>>g/JӦMk׮mRn߾]sSKEbTGhjhjB%4T2$RLUq+V땧lM&d_咋k:  /Qg}mDRӼysm ݻw SD F zv> T֫z`6irZ1  .c>J;w6Ǐ*;n8Jx &:5S;#@T3T҈+W<~2zPٳg>`jB ΄3/СjJ4ԃ꣏>pw@؉*G]U(-Xcǎ}ǭL@Ak1Uu>|M`˫Tז-[z͛GH SU&=ի>z׿5iҤ?V@Sc @(S.@:h'*$Uwf}vmިQ#].I  GIq4//bœ%VT)---77W-D?,8gs־?z[ ?syIIEǓ NʕXbvTұJ\X{¡9 PJ(%HLMII)((cB ~!Æ +h=5Rݗ?rԦQ=zr&FDٻwojM6 N=pٶG> ފj.IWԴ[mvu“%Ӵivin? VL5uTU] ,j1oWOKS;%/0;hK[rBۛ_~崴gA˘ }ڶm+ĵk 6UV~.ExͳI HQwCKP-u}CƎ@ S;vJ3F<ҥ_]&A@ GIE;vp7mTNmQ%nkd!"t? D_[~u?uժUmT-aʕ&..EhG@Hvj#UMJRE@ N }222L$@"' }BiHiӦE@'b 5kF@ $s@13@;T; 1s@;T; 1s@;T; 1s@;TwƋOgE q'P[C;Yq':Ͽ߀'*J.Ѷc5$IKC+y(5 @ ScP"@ q '8JwL( @| NF@bO{DŽ!ħ15>F=bjɶmzQҫW/޾coOW]-V\٭[7)))[;w#Y!?7&cd̘18wU Ϟ'r[T9}կ_7~6Fe1޽{ p^&ZjURR_>ӧOgY{?}Q/Oٳ Ϟ'2Oc}کQjM2%;;[ Zn֮]ۦM7|ӯP^&7n\QQwܑ gرz,[oUJg}Vdɒ%ҘOFa ݉>y=U/6;՟z,CKT]Qab*D2r]r%K>}̩%믗N5ϓ YfDGyR.,\|G*fז?}Ș6ogN#sСǏ{^??z=r.ideeuɜ6g!F)߅/\[۷=ܣ=MF~ᅭ=A/@2d9Ubz`\!75Szk ༅HeV,~ 濌.9<\x7 9=h;̝5!*Stl۶.f6lkVx؍lj֯_Wc=^,5\SF ] 77Ji,FD׽{O=z)Y&bСCŢ2+Jq?=ORfM*wy֜*k[9$E7nٳ'FW.0ήLd#.,ƍͅ;g=/&~O}ylݺ5z=TѳDγ~a7ϲ|g/f 7?ȳL֭[gN-{0*W^@#T; 1s@;T; 1s@;T; 1s@;T; 1s@;T; 1s@;T; 1sfIgT{~FMo#Muw׮];%%zz*Ǻ&d0aBVkN}ܹAmܤIʕ+תUo߾? Z`zcQ19a B;;кߧijo9p^=B{tfY4uXT7YMdh-[ 8p@̋O=N1eq!PB&W_ԫk׮Qof vD鎔Q3ؼyr8rHТ.|+1 _y=X`xb_\hx ˑep~ZhuMXTTZR%mmiO|9hXX(U`n4P!SmVNSX/-cǎ0j֤$|xرٳgׯ_loժU1[H!bj`6߸;ìT?o;sϩ!Ы_Ws󭂂?OUOKϟ_\ oΜ9/^]Xw/~ 7PfM%Т9urƍ@71;5u~RwFl1|wl hqb;5As :0ӒsRSտQ z/+[h@G'I\?sNRO4ES׌ St%ݗ?/<2+OLMģJ8uFՇOj][wP߯ڲ/i`gW}洍,Q siVqK!H6;HY_ŭ1^ kIgXTJ ݚjYeäldE-)hH;w:ҕ UQs$fq)䒓gԥԹ%,ɺw!! I`FxX}Dg̈́(Ce"np+}W莞pKKz!;}٧^q(!p,&s>6$k^nZ#̈́E@2p"[Bob Dc*RxnG q!7@[#@ 7ǻYxqLؤW~ý9'29]%DUxϧ9N"!lI|8h]UW({;k0Tq@Xh։%xV߇ !Լe+Je Vd`5<<M6/sQ&+$ IRrsI{]Ttl. -%N*38&4wא4)JQrM32 5Wgǻhֻx֛n|(@ Jc0ᘽfՃ!ƌgdp ]6ޛ @߫g‚Btу͞G0T9 p Pv9vTHeak ijEkR"{]V:u@]4@ňerRutjx,PC$jdmDLB`V@qAE.ڄ.[}Ex*k\y?As,8e0C$)#K.88xxO-rM޵ג-jʼn8uxL-{ I 5gk X&P&AJخd/dRJ5WA٬EZ#lKУatPxW Yzǃ,1hٳgo(} bCp% p•mmm9cd+Y? @] ѪpVE0L0¡:)v:qqv3$3-_uLGk`\0X[[p9IDhQLWc[Y"@jy"HgS`8ލ',w=|Nk.@ctL `ba.M8`UWW7 o CA(Iu@ѭ Iಝ l:!1-VJ"\PW.XR4D$.9P.[d'5ys,it$Rh2khFm}֍z +Qʜm-<*T REiz2g=C8R@A0چ߬CJR#ddddppphhhtttll ZZZV\ r* :\T*˖-;ڄC4Bqphk\%g\ovQE$G %&>n }\y~HP @#cwYJ-1NxH&pzɁ-\\iD7u{&D!CXf2=,XaE +y5VGmv{ >Dt'ge289r$pB΍sA`lG-ZJ~) Ѿs5a1"-=aA7 - Ph\nۮ~oTVTZ#IyXp]1͏8x&6aaAXt W,Px}ZAJ3dD }Bñp; zlݱz|[I #hÌ$"_&YcJZY1fز8'4f yZ| .QR aE5|",)@6E3p\. 0YYPhXW!Kj|dYN,C#v'NXXxƲGPxdӦuli`X60ɋuER2$P'$<(@ˢB @CTd7Lv͠O/^cxOK/2T.Q5ԴH[ 2(.*_ogV:3/{4ф\ĺtdgȒ܃^UzP 5v'0w rf0p! 2HXh3L&b*PmK5&ʍmf@-oiĔó5N' x⩧vzg[njoGLt4Zli}usYb?uh8LA6X8fy۶mGN? /6`؉X ٽ{f߶t޸i? sQbPsny!q$;2m{ 9b?K REYcQ @e&a Evm%5ʊWҋO!nq:2B/Wq7I%j_I( /knl/{-rm.%,p\cYͣ~&'-\:2?榖=P :0Cb`6RKYAyJ#Q%AѲ ]&& lbjJd9dBnP/%RA P'j ZKlA9'ug ,xS-,H)wز-űo߿u^k{&,_u23دϽr>;j!y)W9 E4pm], lo$9$YbbȘ~ Sd A,Y gW4(s! w&0L6547M51N2gn,X)woz4V(5}̥(%;XCuTY.ywg 0\AemUʮϷ1$"xd\CvmH (k׀PBH֟ phsJf$c2PwT,/Z B6ԨRYEA+V* gXn*@nR(ݪPS>zW y{ak/X_9^T#I̗Hy.X2 JGͬb \bZqִ51PFrY2'i ES'@_`-uБb T9h3 ;˵# f7 \;D*4bF,X֭]IgFSE˃1 MTX.C<̿޽;9s.R7cDӾ)S(?hٷOJsMNZNNpq+,32-hpdxě)p|DRN%4Z)DΉʞKۇJEKf #VE"Ԟ>b#.bA-kr{n[/Ϭ!s%kp ,0Yx{a9>޴>PYvB" ʎRPC)?rmJ9g;ڎ׳Xb:>Zx2,hPv wV Ŋ9cj1gq.XIV}j%ՆXm5E~kEEhE@YS2ɸ4˒z1BH0gMk;KOS=mg2rYG(yy!`c:k‚h_YwV0<9 :CLVIw綇:6cNz?r0;"\r:ԇ"pyӪGID CBQ!"(n,tz~:6a)JhIt F ji2{j}Sn7+,*DA( `Cm|aHi~zP,A]˱ed kw Oִ)_qgi2}S>)rL1]pdT1e e] e!"$A/[|: ly}I%A, [={XF3.:- Ea@G$Nx*A?oxdHXlD ~B^~g΂Gr2 t} $Ÿ',VMʩх3a 39b)ㅵqaP{D)Bnx+˱xXHe3VmӼpaGG:C cH~QAlG?SV>9j(`uuȦrSQw\b /ļIDZ8:ų0<%㤯ommۯ))E$-=QȐ [V J͏jW8ZA+EgNx+ M$=!E;*,k~ѕJkGH'W̭ xwp` ZϹJ<ބ ++ 7v#J*V^&K!)^OAMϱ"eЄX|B/ {'M>ߢ!?& +/EM' n˓ x~İ*8{8Y~ +憆lަTA4[eUҐU,TBwQl^h@N D^YJMFBC5B;Ԩ%4]My<ږ2gؠT.nm˶!LV'ˎ,+%AQ^QI[?L$ 7>$Fl^! 3||ҽp")U\/".7IF!oU1'AR \;Tlal F7&, yLjv@4-xmV^GsmB] TUha+{a! b>>Rnxp,Y[+ Rr+ȗ@T E5M6xtd F,(aG Ȼ>PR9Q,jpn,T+t5TH]aUHGi *"-$3ɢR*R62d3 LxOŋxOe<>ֿZ'4ʦ )@4SY#lT $rT1IEld ?Hb죧Ė/M(lQX\I.22%YB 2;_qCP"Dl|*$51ڼg8Rj0 [7/wowLA)Q)9tp ԁͲ0`q/>{ 7{5ٸ-篻ipx(oꛞx=?Ŏd,z/~97gLpǟZ/Kg6/TE[zg}ێo֪P8 'b7⟞8uROoS}嗿{mm'~Nj?`{3λ Mw˖tv`?$1Ikzp!.^p庵@믿g:p38#{ч/YlUtu2{DŽD¤¼|/f29  h~fk;㒋ϛp~I qڳ}nd]x|Dnmx |%_-D"Gҹɳ%ILؤ)V8iDMhuqhp*v.sg\k{ﯻ*⫇G E[z4/\ݽ]bÜοcV=ݹ\龧EDlw d>PY''-[Uð3.C C!M+*9{Sb< `_ Dȃ #_ÇC |ewu\ F@׿>}zmRփСbO/K:>J9fu"!-Ƅ?3K4a:;;95M ,474!,Y2?{ᬬ""/kX͕`1bd{b,gKJl/C,>0f1\  G+WLF@Ry ɀD=5_2 Jc:!͓\ 4%%(<%a$H{kD^>Oerɪ0X+BX[k8RDz?Vזju}|/ 2>Ua+~?/A˄=IAy2 )6DumY03 Yoa/ƪ'.V$1BH݈7x;qcWW.@ތ2W9m"U{|9aT3'ug"}d "]2YlD$R4KVs,rjȢ@F9=B݅n T5E+exVCY8u0#IC P3k(.0Qd9 8#G#h4SHpd7d1Kd@q-N8) 󗾄|o_~E޹g_GuIdhvl6gV՟/Z:@C=ŗo=T_M=l _=;0co PV -477^ƛn;w /lwٻ=}Ŏ;wuikoxᇦN^w?e),iX7u?qG"Ã7ZiXnx~=`xx)?n}xd:z~֡Y?'TIer4e9kɎ(f׾{Ƕ}&_5TҺm2e҇69i?33_IK72m\ɑԈ.XC|UݩΏ55 ΫGz4д}NY@)>]QZrW^W6Ƙֲ(DV9mu[c Ap=#A! 7ڛ_w%cƹ u)+Vg}'TuLm{tKp}~ ֪ -[u" Ki\?nÁMn\8\@i*DÊU/] l 7|XXiT1φ~½b )'E! (K!WIH}M&48q@bE.ϟ;wO? ]=s̕g̚1cH?z'c766.xPSA)}XsO`0pp"p#p4pj5pE<4dddd<v 0p <4BdBd< 0p___PPT10D[SOalā0 ʛ ppO 0DArialā0 ʛ ppO 0 6___PPT9{?  %X  /   0` 4f` Ϙ``0`0ff` PWP0ff` :ff` #6gff` #60`ff` KKKff` ڻRff` `ff` ϟ0g0ff` f>?" dd +z?" ddk  " g    @ n?" dd@   @@``PR      @` p:   >     %P(  P~ $P 0S"?F+` !P s *":"N P H@;Y;Y"" O# 2TEMPLATE DESIGN 2008 www.PosterPresentations.com:300 A2FF   @@ P TA;Y;Y "_AE  T Click to edit Master title style! ! P NDN{N{N{N{ #" `:"  g-Click to edit Master text styles Second level !  .l P 6g "Fp#`  P s *"""` "P s *"#4"` #P s *"j5E"`B %P s *D)"+F+H P 0ޚ ? #6gffD<___PPT10..j{[n Custom Designr   0` 4f` Ϙ``0`0ff` PWP0ff` :ff` #6gff` #60`ff` KKKff` ڻRff` `ff` ϟ0g0ff` f>?" dd +z?" ddk  " g    @ n?" dd@   @@``PR      @` p:   >      T(  f  0"F+f  0":"~  0fS"?+FOK  Hs;Y;Y"" U# /POSTER TEMPLATE BY: www.PosterPresentations.com:000 A2FF   @@  T\w;Y;Y "_AE  T Click to edit Master title style! !  NN{N{N{N{ #" `:"  g-Click to edit Master text styles Second level !  .l  6g "Fp#f   0"4"f   0"j5E"H  0ޚ ? #6gffD<___PPT10..j{[n 1_Custom Design   0` 4f` Ϙ``0`0ff` PWP0ff` :ff` #6gff` #60`ff` KKKff` ڻRff` `ff` ϟ0g0ff` f>?" dd +z?" ddk  " g    @ n?" dd@   @@``PR      @` p:   >    0 x(  f  0"F+f  0"E"~  0fS"?+FOK  HΛ;Y;Y"" U# /POSTER TEMPLATE BY: www.PosterPresentations.com:000 A2FF   @@  T=;Y;Y "_AE  T Click to edit Master title style! !  NN{N{N{N{ #" `AE"  g-Click to edit Master text styles Second level !  .l  6g "Fp#H  0ޚ ? 4fD<___PPT10..j{[n 2_Custom Design 0 zrL (  L L 0Ti" P   " P*   L 0    " R*  d L c $ ?  " L 0n"  0 " RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S L 68v" _P  " P*   L 6D{" _  " R*  H L 0޽h ? 3380___PPT10.nM~ 0 }} J 0   !"#$%&'()*+,+-./01213|(    H/Y/Y#" `H 9Features of Epstein Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) unrelated umbilical cord blood transplantation (UCBT)F]f(&(6f(]6   @@  _ B]o]o"`:`  Introduction( 0( 2  ggg( a H]o]ooS"`?j5EB  Discussion( 0( 2  ggg  b B ]o]o"`j5E  Conclusions( 0( 2  ggg g HPqqqq"`~j5E =Overall, this study shows the rate of EBV reactivation after RIC UCBT to be relatively low (15%) and this is comparable to the incidence expected with PBSC or BM unrelated mismatched transplants. However, close EBV monitoring and the use of pre-emptive rituximab treatment appears to be mandatory since some cases may progress to LPD requiring additional interventions such as EBV-specific CTLs..` `B Q gg i H qqqq"`j5Ew___PPT10h`>___PPT9  3The absence of EBV-specific memory T cells in UCB grafts, more frequent use of HLA-mismatched grafts, and use of ATG inducing in vivo T-cell depletion all contribute to a higher risk of EBV-related complications in the subset of patients after UCBT.(3) However, as we observed no increased risk of EBV complications in our group of patients, even when ATG used, other factors may modify the risk. Recent evidence-based guidelines from the European Conference on Infections in Leukemia recommended weekly screening of EBV-DNA for at least 3 months in high risk allo-HSCT recipients. In addition, other studies suggest that preemptive therapy with rituximab may be highly effective in controlling viral proliferation and avoiding progression into EBV-related LPD (4). In the current series, the response rate to pre-emptive rituximab appeared to be similar to that previously reported in the literature.(5) In rituximab-resistant patients, options include chemotherapy regimens such as CHOP or EBV specific CTL lines generated using EBV-transformed lymphoblastoid B-cell lines.p41` )` ` ` ` '` ` ` 0` ` ` ` ` "` ` @ `  s` 8` ` M$`$( (,`,0 04`48 8<`< ` ` ` `!R` 1) %0 "   @  k 8  E           7    g_W  j B\?]o]o"`: Patients and methods(0( 2ggg; l Zqqqq?3"`8___PPT10N___PPT90( In all, 33 consecutive patients who received a RIC UCBT for hematological malignancies in a single institution (University Hospital of Nantes) between January 2005 and June 2009 were included in this retrospective study. During the first six months after allo-HSCT and in patients treated for GVHD, all patients were weekly DNA-PCR screened in the peripheral blood for EBV reactivation and were clinically monitored for clinical features attributable to EBV. EBV viremia was defined as 1000 copies of EBV DNA /105 cells. EBV LPD was defined as biopsy- or autopsy proven post-transplantation lymphoma, or viremia along with computerized tomography nodal or soft-tissue abnormalities consistent with LPD. Patients with EBV viremia >1000 copies on at least two consecutive occasions were treated with rituximab at a dose of 375 mg/m2 weekly until clearance of EBV viremia (usually for a maximum of 4 infusions). p`#`h<`hN``"      n  F   6  )  } HD e e e e"  h.  ` 2 ~ BtA]o]o"`4` Results(0( 2ggg  H8Uqqqq"`!"a Patients' characteristics are summarized in Table 1. The median age was 50 (range, 18-66) years. 58% (n=19) of the patients had a myeloid malignancy, 36% (n=12) had a lymphoid malignancy and 6% (n=2) had severe aplastic anemia. 91% (n=30) of the patients received 2 CB units and 9% (n=3) received a single CB. Patients received a median of 4.0x107/kg (range, 2.2-5.8) total nucleated cells and a median of 0.9x105/kg (range, 0.2-3.7) CD34+ cells. Donors and recipients were mismatched with one mismatch in 43% of cases and 2 mismatches in 57%. A RIC including fludarabine (200 mg/m2 total dose), cyclophosphamide (50 mg/Kg) and low dose TBI (2 Gy.) was used in 29 cases (88%), while 8 patients (24%) who were not heavily pretreated before UCBT received ATG. ` T` #`h` ?`h` E` ``h` `5T8*%K  nX  0A?A  N08A8AB )Unrelated umbilical cord blood (UCB) is now being increasingly used as an alternative stem cell source for allogeneic stem cell transplantation (allo-SCT). Because of the slow kinetics of immune reconstitution after UCBT, previous studies showed that EBV reactivation and EBV induced lymphoprolipherative disease (LPD) may be of matter of concern.(1) However,more recent studies reported an infectious-related mortality (IRM) incidence similar to that of allo-SCT using HLA-matched unrelated donor. (2) This single centre study assessed incidence and predictive factors of EBV reactivation and LPD in 33 consecutive patients undergoing RIC UCBT.z e`6 ` ;` @` `2 6+ .-f k B w w"`o=F c ; Z Peric,1,2 X Cahu, 1 P Chevallier,1 E Brissot, 1 T Guillaume,1 J Delaunay,1 S Ayari,1 V Dubruille,1 S Le Gouill,1 B Mahe,1 T Gastinne,1 N Blin,1 B Saulquin,1 N Milpied,1 R Vrhovac, 2 JL Harousseau,1 P Moreau,1 M Coste- Burel,3 BM Imbert-Marcille,3 and M Mohty 1 1 CHU de Nantes, Hematology Department, Nantes, France 2 University Hospital, Hematology Department, Zagreb, Croatia 3 CHU de Nantes, Laboratoire de virology, Nantes, France `T gogogogo go go go go go gogo go go gogo gogogo gog&gT        +                         @@ m Nh f fc#4W8___PPT10N___PPT90( Engraftment occurred at a median of 12 (range, 8-60) days and 15% of patients developed grade 2-4 acute GVHD. The median follow-up for surviving patients was 468 (range, 92-1277) days. EBV reactivation was observed in 5 patients (15%) at a median of 132 (range, 85-438) days after UCBT. The cumulative incidence of EBV viremia is shown in Figure 1. Among the 5 patients experiencing EBV reactivation, 2 patients received ATG as part of their RIC. Four patients were treated with a median of 3 (range, 1-8) rituximab infusions. Two patients responded to rituximab, but 2 patients developed LPD. One of these 2 patients died before receiving any other anti-EBV therapy. In the other patient, LPD could be controlled after additional chemotherapy and 2 infusions of EBV specific cytotoxic T-lymphocytes. Of note, there was no significant difference in overall survival between patients with or without EBV reactivation (p=0.33). N(2`:` F`     &fII? n Hx f fA:! ]CONTACT: Zinaida Peric, MD; University Hospital Centre; Zagreb, Croatia zina_peric@yahoo.com^022^^IIN o Tx= f fj5Ex":2___PPT10|t___PPT9h` ^Brunstein CG et al. Marked increased risk of Epstein-Barr virus related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108(8):2874-2880. 2. Parody Ret al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12:734-748 3. Clave E et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load EBV-specific T-cell reconstitution and rituximab therapy. Transplantation. 2004;77:76-84. 4. Wagner HJet al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979-3981. 5. Faye, A et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B- lymphoproliferative disorder following stem cell transplantation in children. BrJ Haematol 2001; 115, 112 118.4 b  :b   b  " 0b " 8b " Cb " 8b " b b  " $b$ $"$ 0$b$ ("( 0,b, 0"0 04b4 8"8 (wwew#"   Td= w w?~j#  12 (8-60) nnII   T$i= w w?j~ Engraftment days (ANC>0,5) nnII'   T= w w?~#j  4.0 (2.2-5.8) $nnII5   Tl.= w w?~j TNC count/106 kg BwD B J B nnII   Tt= w w?~!#"  34 (9-112) nnIIP   T,= w w?~#! X 28 (85%) 3 (9%) 2 (6%)YY YnnII   T4= w w?~I#  0.9 (0.2-3.7) nnIIM   TԻ= w w?~#I U 1 (3%) 32 (97%) VV VnnIIb   TL= w w?~m# j 8 (24%) 25 (76%) 29 (88%) 4 (12%)kk knnII6   T= w w?~#m > 14 (43%) 19 (57%) ?? ?nnIIS   T= w w?~d# [ 3 (9%) 30 (91%) \\ \nnII:   TH= w w?~#d B 6 (18%) 27 (82%)CC CnnIIC   T= w w?~# K 19 (58%) 12 (36%) 2 (6%)LL LnnII)   T= w w?~# 1 20 (61%) 31 (94%)22 2nnII   TD w w?~p#  18: 15 (55%:45%) nnII   T  w w?~#p  50 (18-66)  nnII!   T w w?!~" Acute GVHD days after alloSCT&B  nnIIT   T w w?~! *acute GVHD Grade 0-I Grade II Grade III-IVL+ B  B  +nnII6   T8, w w?I~ CD 34+ count/105 kg BwBB   B  nnIIR   T6 w w?~I BImunosupression Cyclosporine (CSA) CSA+mycophenolat-mophetil (MMF)2C# B  CnnIIj   TC w w?m~ 6Conditioning with ATG without ATG with TBI without TBIV7  B  B   7nnII%   TTN w w?~m %HLA matching 1 mismatch 2 mismatches "&%  &nnII"   T& w w?d~ "Number of CBT units Single Double "#"  #nnIIX   TTc w w?~d 6Disease status Standard risk disease High risk disease<7 B   6nnIIX   T@o w w?~ LDiagnosis Myeloid malignancies Lymphoid malignancies Severe aplastic anemia&M  CB LnnII9   Tz w w?~ 5CMV seronegative recipient EBV seropositive recipient&6B 2 6nnII   Ts w w?p~ Sex ratio (M:F)& B  nnII'   T} w w?~p Patient age (median, range)& B  nnII`B   01 ?#ZB   s *1 ?p#pZB   s *1 ?#ZB   s *1 ?#ZB   s *1 ?#ZB   s *1 ?d#dZB   s *1 ?#ZB   s *1 ?m#mZB   s *1 ?#ZB   s *1 ?I#IZB   s *1 ?#ZB   s *1 ?!#!`B   01 ?"#"`B   01 ?"ZB   s *1 ?~~"`B   01 ?##"ZB   s *1 ?j#jZB   s *1 ?#X  0A?*&.5f  0A?"`/*&.!  H f f'+- xP = NS 2"fII  H f f;n*. Without EBV reactivation 2 II  H@ f fn*.[ With EBV reactivation 2 IIH  0ޚ ? 33___PPT10i.H[0QT+D=' == @B + 0 P&(  P^ P S L   " P S h"L 0  " "H P 0޽h ? 3380___PPT10.NsMr,b6 @`0"H%s @1Oh+'0}$P\ ht   72x36 Poster Template$Free PowerPoint poster templates A. Kotoulas4poster presentation, poster design, poster template$Non-authorized printing of this poster template by any commercial printing service other than PosterPresentations.com is strictly prohibited. Non-profit educational printing centers are exempt. To obtain printing authorization call: 1.866.649.3004 2007 Canterbury Media Services, IncRV194Microsoft Office PowerPoint@PZ@0?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abdefghijklmnopqrstuvwxyz{|}~     Root EntrydO)PicturesCurrent UserSummaryInformation(8}PowerPoint Document(cDocumentSummaryInformation8